In a subgroup analysis of the patients of the TGCA cohort, stratified for the different BC molecular subtypes (i.e. luminal, Her2+ and triple-negative-TNBC), we recently reported that, compared to luminal and Her2+ patients, TNBC patients showed significantly reduced expression levels of SRCIN1 transcript and p140Cap protein levels, indicating that BC with clinico-pathological features of aggressiveness, such as TNBCs, display comparatively lower level of the tumor suppressor p140Cap [31]. Here, ERBB2 is linked to breast cancer.